Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

125 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Plasma Cell-Free DNA Integrity Assessed by Automated Electrophoresis Predicts the Achievement of Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer.
Cirmena G, Ferrando L, Ravera F, Garuti A, Dameri M, Gallo M, Barbero V, Ferrando F, Del Mastro L, Garlaschi A, Friedman D, Fregatti P, Ballestrero A, Zoppoli G. Cirmena G, et al. Among authors: ferrando l, ferrando f. JCO Precis Oncol. 2022 Feb;6:e2100198. doi: 10.1200/PO.21.00198. JCO Precis Oncol. 2022. PMID: 35201850 Free PMC article.
High-dose mitoxantrone with peripheral blood progenitor cell rescue: toxicity, pharmacokinetics and implications for dosage and schedule.
Ballestrero A, Ferrando F, Garuti A, Basta P, Gonella R, Esposito M, Vannozzi MO, Sorice G, Friedman D, Puglisi M, Brema F, Mela GS, Sessarego M, Patrone F. Ballestrero A, et al. Among authors: ferrando f. Br J Cancer. 1997;76(6):797-804. doi: 10.1038/bjc.1997.465. Br J Cancer. 1997. PMID: 9310249 Free PMC article. Clinical Trial.
The induction of distinct cytokine cascades correlates with different effects of granulocyte-colony stimulating factor and granulocyte/macrophage-colony-stimulating factor on the lymphocyte compartment in the course of high-dose chemotherapy for breast cancer.
Setti M, Bignardi D, Ballestrero A, Ferrando F, Musselli C, Blanchi S, Basso M, Bosco O, Balleari E, Patrone F, Indiveri F. Setti M, et al. Among authors: ferrando f. Cancer Immunol Immunother. 1999 Sep;48(6):287-96. doi: 10.1007/s002620050577. Cancer Immunol Immunother. 1999. PMID: 10473803 Free PMC article. Clinical Trial.
Comparative effects of three cytokine regimens after high-dose cyclophosphamide: granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor (GM-CSF), and sequential interleukin-3 and GM-CSF.
Ballestrero A, Ferrando F, Garuti A, Basta P, Gonella R, Stura P, Mela GS, Sessarego M, Gobbi M, Patrone F. Ballestrero A, et al. Among authors: ferrando f. J Clin Oncol. 1999 Apr;17(4):1296. doi: 10.1200/JCO.1999.17.4.1296. J Clin Oncol. 1999. PMID: 10561192 Clinical Trial.
Adjuvant chemotherapy with high-dose cyclophosphamide, etoposide and cisplatin intensification without progenitor cell support in breast cancer patients with ten or more involved nodes: 5-year results of a pilot trial.
Ballestrero A, Rubagotti A, Stura P, Ferrando F, Amoroso D, Rinaldini M, Sismondi P, Genta F, Mesiti M, Brema F, Patrone F, Boccardo F; GROCTA (Italian Breast Cancer Adjuvant Study). Ballestrero A, et al. Among authors: ferrando f. Oncology. 2001;60(3):221-7. doi: 10.1159/000055322. Oncology. 2001. PMID: 11340373
125 results